CN111662871A - 一种核酸适体功能化nk细胞及其制备与应用 - Google Patents
一种核酸适体功能化nk细胞及其制备与应用 Download PDFInfo
- Publication number
- CN111662871A CN111662871A CN202010530479.5A CN202010530479A CN111662871A CN 111662871 A CN111662871 A CN 111662871A CN 202010530479 A CN202010530479 A CN 202010530479A CN 111662871 A CN111662871 A CN 111662871A
- Authority
- CN
- China
- Prior art keywords
- cells
- cell
- aptamer
- icg
- functionalized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091023037 Aptamer Proteins 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 210000000822 natural killer cell Anatomy 0.000 claims abstract description 77
- 210000004027 cell Anatomy 0.000 claims abstract description 68
- 201000007270 liver cancer Diseases 0.000 claims abstract description 26
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 26
- 238000006243 chemical reaction Methods 0.000 claims abstract description 23
- 230000000694 effects Effects 0.000 claims abstract description 20
- 238000009169 immunotherapy Methods 0.000 claims abstract description 11
- 239000012528 membrane Substances 0.000 claims abstract description 6
- 230000023852 carbohydrate metabolic process Effects 0.000 claims abstract description 3
- 229960004657 indocyanine green Drugs 0.000 claims description 48
- 102100032530 Glypican-3 Human genes 0.000 claims description 19
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 claims description 19
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 11
- 238000012258 culturing Methods 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 7
- 239000006143 cell culture medium Substances 0.000 claims description 6
- QRZUPJILJVGUFF-UHFFFAOYSA-N 2,8-dibenzylcyclooctan-1-one Chemical compound C1CCCCC(CC=2C=CC=CC=2)C(=O)C1CC1=CC=CC=C1 QRZUPJILJVGUFF-UHFFFAOYSA-N 0.000 claims description 5
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 5
- 229930182566 Gentamicin Natural products 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 229960002518 gentamicin Drugs 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 230000004060 metabolic process Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
- -1 azide modified mannose Chemical class 0.000 claims description 3
- 150000001540 azides Chemical class 0.000 claims description 3
- 150000002703 mannose derivatives Chemical class 0.000 claims description 3
- 230000001502 supplementing effect Effects 0.000 claims description 3
- 210000002993 trophoblast Anatomy 0.000 claims description 3
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 claims description 2
- 230000003203 everyday effect Effects 0.000 claims description 2
- 239000002609 medium Substances 0.000 claims description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 39
- 238000007626 photothermal therapy Methods 0.000 abstract description 15
- 210000004881 tumor cell Anatomy 0.000 abstract description 15
- 230000008685 targeting Effects 0.000 abstract description 11
- 230000002195 synergetic effect Effects 0.000 abstract description 6
- 238000002560 therapeutic procedure Methods 0.000 abstract description 4
- 238000003384 imaging method Methods 0.000 abstract description 3
- 230000008595 infiltration Effects 0.000 abstract description 2
- 238000001764 infiltration Methods 0.000 abstract description 2
- 238000011068 loading method Methods 0.000 abstract description 2
- 230000001404 mediated effect Effects 0.000 abstract description 2
- 238000012544 monitoring process Methods 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 230000003287 optical effect Effects 0.000 abstract 2
- 239000000523 sample Substances 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 5
- 238000000799 fluorescence microscopy Methods 0.000 description 4
- 239000002086 nanomaterial Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 3
- 208000007660 Residual Neoplasm Diseases 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000012642 immune effector Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 229930192851 perforin Natural products 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000012137 double-staining Methods 0.000 description 2
- 238000005206 flow analysis Methods 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- 102100030385 Granzyme B Human genes 0.000 description 1
- 101001009603 Homo sapiens Granzyme B Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0006—Modification of the membrane of cells, e.g. cell decoration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/34—Sugars
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明公开了一种用于近红外引导下免疫/光热时序协同治疗肝癌的核酸适体功能化NK细胞及其制备与应用。本发明通过糖代谢途径将核酸适体共价偶联于NK细胞膜表面(G‑NK)，赋予其对肝癌的靶向作用；利用G‑NK细胞负载近红外荧光/光热转换分子ICG，构建免疫/光学时序性治疗载体系统(ICG@G‑NK)；以ICG作为分子影像探针，实现近红外荧光监测G‑NK细胞对肿瘤的富集，进而精准获取肿瘤的位置信息；在实现G‑NK细胞介导的免疫治疗后，启动光热治疗(PTT)，进一步杀伤残存肿瘤细胞；同时PTT可破坏实体瘤的致密组织结构，进一步促进G‑NK细胞富集和浸润，达到免疫/光学时序性协同治疗肝癌的目的，这将为NK细胞用于肝癌的综合治疗提供新策略。
Description
(一)技术领域
本发明涉及一种核酸适体功能化NK细胞，及其制备方法以及在制备肝癌过继性免疫治疗药物中的应用。
(二)背景技术
根据国家癌症中心发布的《2019中国最新癌症报告》显示：我国新增癌症病例中，肝癌发病人数位列第四，死亡率排名第二，严重威胁着我国人民的生命健康及生活质量。尽管目前肝癌治疗以手术切除为主，辅以放疗、介入治疗等综合治疗手段，获得了一定的治疗效果，但预后仍较差，肝癌患者的远期生存率仍较低。
基于NK细胞的过继性免疫治疗是一种不依赖于抗原预先致敏而直接识别与攻击肿瘤细胞的免疫细胞治疗策略。NK细胞具有良好的杀伤肿瘤细胞特性，通过分泌TNF-α、IFN-γ、颗粒酶及穿孔素等细胞因子诱导肿瘤细胞凋亡或坏死。NK细胞不需要抗原预先致敏就能直接识别和攻击肿瘤细胞，并且NK细胞具有良好的组织浸润能力能够快速浸入肿瘤组织内部，因此受到业界普遍关注。但是NK细胞缺乏肿瘤特异性靶向能力及其体外扩增效率较低，限制其更深入的临床运用。基因工程/嵌合抗原受体改造的自然杀伤性细胞(CAR-NK细胞)能够通过其表面表达的scFv片段特异性识别肿瘤细胞，促进NK细胞向肿瘤部位富集，是提高NK细胞靶向能力的有效手段之一。但是，由于实体肿瘤组织间质致密以及免疫抑制微环境导致免疫治疗效果有限，以及CAR-NK细胞存在制备工艺复杂、成本昂贵等问题，极大的限制了其临床推广应用。
多手段联合治疗是提高肝癌治疗疗效的重要策略。免疫细胞治疗与光热治疗具有天然的联合和协同治疗基础，将其联合能够有效提高实体肿瘤的治疗效果。光热治疗(Photo Thermal Therapy，PTT)是利用近红外光照射，促使光热转换物质(如ICG、PDA等物质)将光能转化为热能，导致肿瘤细胞受热坏死的治疗手段。它具有无创、选择性高、无肿瘤耐药性等优点，能够在肿瘤免疫抑制微环境下发挥肿瘤治疗效果，并打破实体肿瘤致密的组织结构，进而吸引免疫效应细胞进一步浸润肿瘤组织，实现对残存肿瘤细胞的免疫杀伤。
当前免疫治疗联合光热治疗的策略主要是通过将光热转换物质包裹在各种肿瘤靶向/响应的纳米材料中使其靶向富集于肿瘤部位进行光热治疗，再辅助回输免疫效应细胞，从而形成简单的联合治疗方式。该联合治疗方式依赖于复杂的具有肿瘤靶向富集、成像、光热转换性能的纳米材料，两者之间难以真正有效协同，且存在纳米材料的长期安全性、免疫细胞肿瘤部位富集动力学不清楚等诸多问题，距离临床应用遥远。
兼具荧光成像功能的免疫/光热联合治疗更具临床转化与应用优势，首先，荧光成像具有较高的时间和空间分辨率，能够实时动态、可视化监测免疫细胞在肿瘤部位富集，进而精准为光热治疗提供肿瘤的位置信息；其次，免疫细胞在肿瘤部位富集与光热转换物质体内代谢都具有一定的时效性，准确判定最佳光照时机能够进一步提高免疫/光热联合治疗效果。
(三)发明内容
为了解决上述技术难题，本发明提供了一种用于近红外引导下免疫/光热时序协同治疗肝癌的核酸适体功能化NK细胞，及其在在制备肝癌过继性免疫治疗药物中的应用。
本发明采用的技术方案是：
一种核酸适体功能化NK细胞，由如下方法制备获得：
(1)制备PBMC细胞，与滋养细胞IL21-K562共培养，获得体外激活扩增NK细胞；
(2)步骤(1)获得的NK细胞经叠氮修饰甘露糖(Ac4ManNAz)代谢后，在NK细胞膜表面表达叠氮基团，获得糖代谢工程化的NK细胞；
(3)将DBCO修饰的GPC3核酸适体与糖代谢工程化的NK细胞混合共孵育，获得所述核酸适体功能化NK细胞；所述DBCO修饰的GPC3核酸适体的核苷酸序列如下：5’-DBCO-TAACGCTGACCTTAGCTGCATGGCTTTACATGTTCCA-3’
本发明是利用体外激活的NK细胞，经叠氮修饰的甘露糖(Ac4ManNAz)糖代谢途径处理，作为荧光/光热转换物质ICG的载药体系(ICG@NK)，再经DBCO末端修饰的GPC3核酸适体经点击化学手段共价偶联在NK细胞表面获得ICG@G-NK细胞。
本发明还涉及制备所述核酸适体功能化NK细胞的方法，所述方法包括：
(1)制备健康PBMC细胞(采集外周血液30mL，采用Ficoll分离提取PBMC细胞)，调节PBMC细胞密度为0.5～4.0×106个/mL，将其以1:5～10的比例与IL21-K562滋养细胞混合，于NK细胞培养基中培养至第7～8天，调整NK细胞密度0.3～1.5×106个/mL，按照NK细胞:IL21-K562比例1:1～5，补充滋养细胞IL21-K562，每天补充NK细胞培养基至第12～14天，制备获得体外激活扩增的NK细胞；所述NK细胞培养基组分为：IL-2100～300IU/mL，庆大霉素50～100U/mLK，溶剂为BM581培养基；
(2)步骤(1)获得的NK细胞加入叠氮修饰甘露糖培养18～24小时后，加入荧光/光热转换物质吲哚菁绿，继续培养18～24小时，获得ICG@NK细胞；
(3)将获得的ICG@NK细胞加入DBCO修饰的GPC3核酸适体在35～37℃共孵育0.5～1小时，获得具有荧光及光热转换效应的ICG@G-NK细胞，即所述核酸适体功能化NK细胞；所述DBCO修饰的GPC3核酸适体的核苷酸序列如下：5’-DBCO-TAACGCTGACCTTAGCTGCATGGCTTTACATGTTCCA-3’。
优选的，步骤(2)中叠氮修饰的甘露糖添加浓度为0.5～8μg/mL。
优选的，步骤(3)DBCO修饰的GPC3核酸适体添加浓度为0.01～1μmol/mL。
步骤(2)中所述荧光/光热转换物质吲哚菁绿添加浓度为0.1～200μg/mL。
优选的，步骤(1)中所述NK细胞培养基组成为：IL-2 200IU/mL，庆大霉素80U/mL，溶剂为BM581培养基。
本发明通过体外激活培养NK细胞，将NK细胞与叠氮修饰的甘露糖(Ac4ManNAz)共培养，通过点击化学反应将特异性识别肝癌的GPC3核酸适体共价偶联到NK细胞表面，成功构建特异性靶向识别肝癌组织的活化G-NK细胞，G-NK细胞在特异性核酸适体的靶向作用，特异性识别肿瘤细胞，释放细胞因子IFN-γ、TNF-α、穿孔素(perforin)及颗粒酶(GZMB)等，发挥特异性杀伤肿瘤细胞的作用，实现肝癌免疫治疗效果。
本发明通过上述步骤制备的ICG@G-NK细胞，可通过NK细胞膜表面的GPC3核酸适体特异性识别并结合肿瘤细胞，同时可作为荧光/光热转换物质(ICG)的载体体系，实现近红外荧光检测ICG@G-NK细胞靶向富集于肿瘤部位，进而精准获取肿瘤的位置信息；在实现NK细胞介导的免疫治疗后，对肿瘤组织进行精准的PTT治疗。PTT能够打破实体肿瘤致密的组织结构，同时促进血管扩张加快外周血中免疫效应细胞更好的浸润肿瘤组织，实现对残存肿瘤细胞的免疫杀伤，增强肿瘤免疫反应，提升实体肿瘤治疗的疗效，进一步提高肝癌靶向的过继性免疫治疗，具有较好的协同治疗效果。
本发明的有益效果主要体现在：
1)本发明利用特异性靶向识别肝癌的GPC3核酸适体共价偶联至NK细胞膜表面，赋予NK细胞良好的肝癌靶向性，提高了NK细胞对肝癌的主动靶向杀伤能力。
2)本发明利用GPC3核酸适体功能化的NK细胞，能够作为荧光/光热转换物质(ICG)的载药体系，实现近红外荧光检测NK细胞的靶向富集作用，同时精准获取肿瘤组织的位置信息，实现对肿瘤组织进行精准的PTT治疗。
3)本发明利用GPC3核酸适体功能化的NK细胞(ICG@G-NK)细胞完成免疫治疗后精准PTT治疗之后，PTT治疗能够打破肿瘤致密组织结构，吸引更多免疫细胞富集，反过来继续增强过继性免疫细胞治疗效果。
(四)附图说明
图1为本发明近红外荧光引导下的免疫/光热时序协同治疗肝癌核酸适体功能化NK细胞的制备及其应用原理图。
图2为核酸适体功能化NK细胞携带荧光/光热转换物质(ICG)共聚焦图。
图3为ICG@G-NK细胞近红外荧光成像(A)及光热转换效率图(B)。
图4为ICG@G-NK杀伤肝癌细胞流式分析图。
图5为近红外荧光监测ICG@G-NK细胞肿瘤部位富集效果图
(五)具体实施方式
下面结合具体实施例对本发明进行进一步描述，但本发明的保护范围并不仅限于此：
实施例1：
采集外周血液30mL，采用Ficoll分离提取PBMC细胞，调节PBMC细胞密度为2.0×106个/mL，与IL21-K562滋养细胞共培养(培养基组成为：IL-2 200IU/mL，庆大霉素80U/mL，溶剂为KBM581培养基)；在第3天离心，调整细胞密度1.0×106个/mL，补充新鲜的KBM581培养基及IL-2 100IU/mL，硫酸庆大霉素80IU/mL。此后每天补充培养液及相应的细胞因子至第7天，再重新调整细胞密度为1.0×106个/ml，再次添加IL21-K562滋养细胞与NK细胞共培养，培养第12天收获激活的NK细胞。
取1.0×106个/mL活化的NK细胞1mL，加入2μg的叠氮修饰的甘露糖(Ac4ManNAz，陕西新研博美生物科技有限公司)培养24小时，再加入50μg的吲哚菁绿(ICG)培养24小时，获得ICG@NK细胞；采用PBS清洗ICG@NK细胞3次，500g离心5分钟，弃上清；采用0.2mL的D-PBS重悬细胞，加入0.02μM的DBCO修饰的GPC3核酸适体，37℃反应0.5小时；PBS清洗3次，500g离心5分钟，弃上清，获得ICG@G-NK细胞。
实施例2：
取1.0×106个ICG@G-NK细胞，采用近红外光I区和II区激光观察ICG@G-NK细胞成像效果。采用808nm激光，激光功率调整为0.5W/cm2照射ICG@G-NK细胞，观察光热转换效率。
取2×105个/孔的HepG2细胞，铺于24孔板；按照E/T＝10:1的条件，加入实施例1所获得的ICG@G-NK细胞，共培养1小时；洗去未结合的效应细胞，继续培养24小时；收集残余的肿瘤细胞，采用Annexin V/PI双染的方法检测肿瘤细胞存活的差异。
实施例3：
实施例1制备的ICG@G-NK细胞可用于肝癌过继性免疫治疗。收集5×106个的HepG2细胞接种于小鼠皮下，待其成长为100mm3肿瘤大小时，收集实施例1制备的ICG@G-NK细胞5×106个，通过尾静脉过继性输注至小鼠体内，24小时后脱颈处死小鼠，收集小鼠主要脏器及肿瘤组织，采用近红外荧光观察ICG@G-NK细胞的富集情况。
使用荧光标记法及共聚焦显微镜观测核酸适体功能化ICG@G-NK细胞状态，及其靶向杀伤肝癌细胞的细胞状态以及利用流式细胞术检测杀伤后的肝癌细胞凋亡或坏死比例。具体测试结果如下：
(1)近红外引导下免疫/光热时序协同治疗肝癌的核酸适体功能化NK细胞的制备及其应用原理图；
本发明近红外引导下免疫/光热时序协同治疗肝癌的核酸适体功能化NK细胞的制备及其应用原理图参见图1。
(2)核酸适体功能化ICG@G-NK细胞制备；
将DBCO末端修饰的GPC3核酸适体经点击化学反应，共价偶联于NK细胞膜表面，并作为荧光/光热转换物质(ICG)的载体体系。
结果见图2，由图可见，GPC3核酸适配体共价偶联于NK细胞表面，并且NK细胞能够作为ICG的载体体系，携带ICG分子。
(3)核酸适体功能化ICG@G-NK细胞荧光成像效果图及光热转换效率；
采用近红外荧光观察核酸适体功能化ICG@G-NK细胞荧光信号，并考察核酸适体功能化ICG@G-NK细胞的光热转换效果。
结果见图3，由图可见，核酸适体功能化ICG@G-NK细胞在近红外I区和近红外II区均有较好的荧光信号；同时，在808nm的激光条件下具有较好的光热转换效率。
(4)核酸适体功能化ICG@G-NK细胞靶向杀伤肝癌细胞流式分析图；
将2×105个/孔的HepG2细胞接种于24孔板中，37℃过夜培养。第二天将ICG@G-NK细胞以E:T＝10:1的效靶比加入到HepG2中，共培养1小时，采用PBS洗去未结合的NK细胞，继续培养24小时，采用Annexin-V FITC/PI凋亡双染色试剂盒，考察HepG2细胞的凋亡情况。
结果见图4，由图可见，ICG@G-NK细胞能够有效提高NK细胞杀伤肿瘤细胞的效率，其凋亡及坏死比例高达37.0％。
(5)核酸适体功能化ICG@G-NK细胞靶向肝癌组织效果图；
收集5×106个HepG2细胞接种于小鼠皮下，待肿瘤生长至100mm3大小时，通过尾静脉过继性输注5×106个ICG@G-NK细胞，24小时后，脱颈处死小鼠，收集小鼠主要脏器及肿瘤组织，采用近红外光考察ICG@G-NK细胞在肿瘤组织的富集效果。
结果见图5，由图可见，ICG@G-NK细胞可以特异性在肿瘤组织富集。
以上实施例的说明只是用于帮助理解本发明方法及其核心思想。应当指出，对于本技术领域的普通技术人员来说，在不脱离本发明原理的前提下，还可以对本发明进行若干改进和修饰，这些改进和修饰也落入本发明权利要求保护范围内。
Claims (7)
1.一种核酸适体功能化NK细胞，由如下方法制备获得：
(1)制备PBMC细胞，与滋养细胞IL21-K562共培养，获得体外激活扩增NK细胞；
(2)步骤(1)获得的NK细胞经叠氮修饰甘露糖(Ac4ManNAz)代谢后，在NK细胞膜表面表达叠氮基团，获得糖代谢工程化的NK细胞；
(3)将DBCO修饰的GPC3核酸适体与糖代谢工程化的NK细胞混合共孵育，获得所述核酸适体功能化NK细胞；所述DBCO修饰的GPC3核酸适体的核苷酸序列如下：5’-DBCO-TAACGCTGACCTTAGCTGCATGGCTTTACATGTTCCA-3’。
2.制备权利要求1所述的核酸适体功能化NK细胞的方法，所述方法包括：
(1)制备健康PBMC细胞，将其以1:5～10的比例与IL21-K562滋养细胞混合，于NK细胞培养基中培养至第7～8天，调整NK细胞密度0.3～1.5×106个/mL，按照NK细胞：IL21-K562比例1:1～5，补充滋养细胞IL21-K562，每天补充NK细胞培养基至第12～14天，制备获得体外激活扩增的NK细胞；所述NK细胞培养基组分为：IL-2 100～300IU/mL，庆大霉素50～100U/mL，溶剂为KBM581培养基；
(2)步骤(1)获得的NK细胞加入叠氮修饰甘露糖培养18～24小时后，加入荧光/光热转换物质吲哚菁绿，继续培养18～24小时，获得ICG@NK细胞；
(3)将获得的ICG@NK细胞加入DBCO修饰的GPC3核酸适体在37℃共孵育0.5～1小时，获得具有荧光及光热转换效应的ICG@G-NK细胞，即所述核酸适体功能化NK细胞；所述DBCO修饰的GPC3核酸适体的核苷酸序列如下：5’-DBCO-TAACGCTGACCTTAGCTGCATGGCTTTACATGTTCCA-3’。
3.如权利要求2所述的方法，其特征在于步骤(2)中叠氮修饰的甘露糖添加浓度为0.5～8μg/mL。
4.如权利要求2所述的方法，其特征在于步骤(3)DBCO修饰的GPC3核酸适体添加浓度为0.01～1μmol/mL。
5.如权利要求2所述的方法，其特征在于步骤(2)中所述荧光/光热转换物质吲哚菁绿添加浓度为0.1～200μg/mL。
6.如权利要求2所述的方法，其特征在于步骤(1)中所述NK细胞培养基组成为：IL-2200IU/mL，庆大霉素80U/mL，溶剂为KBM581培养基。
7.权利要求1所述的核酸适体功能化NK细胞在制备肝癌过继性免疫治疗药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010530479.5A CN111662871A (zh) | 2020-06-11 | 2020-06-11 | 一种核酸适体功能化nk细胞及其制备与应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010530479.5A CN111662871A (zh) | 2020-06-11 | 2020-06-11 | 一种核酸适体功能化nk细胞及其制备与应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111662871A true CN111662871A (zh) | 2020-09-15 |
Family
ID=72386658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010530479.5A Pending CN111662871A (zh) | 2020-06-11 | 2020-06-11 | 一种核酸适体功能化nk细胞及其制备与应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111662871A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114984214A (zh) * | 2022-05-31 | 2022-09-02 | 华中科技大学同济医学院附属协和医院 | 一种基于羊奶源性细胞外囊泡的诊疗性纳米探针、制备方法及其应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180010097A1 (en) * | 2015-01-23 | 2018-01-11 | Oslo Universitetssykehus Hf | Universal Killer T-Cell |
| WO2019118793A2 (en) * | 2017-12-14 | 2019-06-20 | Ezy Biotech Llc | Subject-specific tumor inhibiting cells and the use thereof |
| CN110055218A (zh) * | 2019-04-22 | 2019-07-26 | 上海瑞可新生物科技有限公司 | 一种人工改造自然杀伤性细胞及其制备与应用 |
-
2020
- 2020-06-11 CN CN202010530479.5A patent/CN111662871A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180010097A1 (en) * | 2015-01-23 | 2018-01-11 | Oslo Universitetssykehus Hf | Universal Killer T-Cell |
| WO2019118793A2 (en) * | 2017-12-14 | 2019-06-20 | Ezy Biotech Llc | Subject-specific tumor inhibiting cells and the use thereof |
| CN110055218A (zh) * | 2019-04-22 | 2019-07-26 | 上海瑞可新生物科技有限公司 | 一种人工改造自然杀伤性细胞及其制备与应用 |
Non-Patent Citations (2)
| Title |
|---|
| 孙红光等: "核酸适配体技术及其在肿瘤诊断和治疗中的应用", 《药学进展》 * |
| 熊非等: "应用纳米技术发展血液恶性肿瘤检测与治疗的新技术和新方法", 《中国基础科学》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114984214A (zh) * | 2022-05-31 | 2022-09-02 | 华中科技大学同济医学院附属协和医院 | 一种基于羊奶源性细胞外囊泡的诊疗性纳米探针、制备方法及其应用 |
| CN114984214B (zh) * | 2022-05-31 | 2023-07-25 | 华中科技大学同济医学院附属协和医院 | 一种基于羊奶源性细胞外囊泡的诊疗性纳米探针、制备方法及其应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110055218B (zh) | 一种人工改造自然杀伤性细胞及其制备与应用 | |
| Corsten et al. | Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare | |
| CN112795533A (zh) | 从细胞培养上清液和生物流体分离并纯化微泡的方法 | |
| CN105779386B (zh) | 一种间充质干细胞在制备治疗m5型白血病药物中的应用 | |
| CN109620956B (zh) | 一种智能巨噬细胞肿瘤靶向治疗系统及其制备方法和应用 | |
| CN103079578B (zh) | 治疗移植物抗宿主疾病的方法 | |
| CN112675202A (zh) | 一种基于靶向配基细胞偶联技术的抗肿瘤免疫细胞及其制备方法与应用 | |
| CN112755925B (zh) | 一种神经组织来源外泌体的提取方法 | |
| CN111235106A (zh) | 一种靶向肿瘤细胞的Aptamer-CD3+T细胞及其构建方法与应用 | |
| JP2016540770A (ja) | 新生物の処置方法 | |
| CN111662871A (zh) | 一种核酸适体功能化nk细胞及其制备与应用 | |
| CN110907416A (zh) | 一种基于空心纳米针管电穿孔系统的循环肿瘤细胞检测装置及其检测方法 | |
| CN114540294A (zh) | 靶向肿瘤部位递送基因药物的干细胞外泌体的制备与应用 | |
| Fernandes‐Platzgummer et al. | Optimized operation of a controlled stirred tank reactor system for the production of mesenchymal stromal cells and their extracellular vesicles | |
| US11920180B2 (en) | Method for inducing differentiation of pluripotent stem cells in vitro | |
| CN114869911B (zh) | Pd-1细胞膜纳米囊泡联合干细胞膜片在恶性黑色素瘤术后治疗中的应用 | |
| CN115029320A (zh) | 用于肿瘤放疗增敏的工程化外泌体、制备方法、应用 | |
| CN113801843B (zh) | 一种增强人尿源性干细胞干性的方法 | |
| JP2022035914A (ja) | 高速かつ効率的にインビトロ増幅ヒト間葉系幹細胞的方法および使用 | |
| CN102028958A (zh) | 以细菌纳米磁小体为载体的复合肿瘤基因疫苗及其制备方法 | |
| JP2011512846A5 (zh) | ||
| CN114540273B (zh) | 一种诱导间充质干细胞向胰岛β细胞分化的方法 | |
| CN115747288B (zh) | 一种肿瘤转移起始细胞的筛选方法与应用 | |
| CN112843256A (zh) | 可在生物体内示踪的细胞、其制备方法及其在细胞药代动力学研究中的用途 | |
| Chen et al. | Genetically engineered probiotics for an optical imaging-guided tumor photothermal therapy/immunotherapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200915 |
|
| RJ01 | Rejection of invention patent application after publication |